172 related articles for article (PubMed ID: 27059620)
1. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol.
Luhar A; Khan S; Finn JP; Ghahremani S; Griggs R; Zaritsky J; Salusky I; Hall TR
Pediatr Radiol; 2016 Aug; 46(9):1332-40. PubMed ID: 27059620
[TBL] [Abstract][Full Text] [Related]
2. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.
Shahrouki P; Moriarty JM; Khan SN; Bista B; Kee ST; DeRubertis BG; Yoshida T; Nguyen KL; Finn JP
J Cardiovasc Magn Reson; 2019 Mar; 21(1):17. PubMed ID: 30853026
[TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.
Ruangwattanapaisarn N; Hsiao A; Vasanawala SS
Pediatr Radiol; 2015 Jun; 45(6):831-9. PubMed ID: 25427433
[TBL] [Abstract][Full Text] [Related]
4. High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol.
Shahrouki P; Khan SN; Yoshida T; Iskander PJ; Ghahremani S; Finn JP
Pediatr Radiol; 2022 Mar; 52(3):501-512. PubMed ID: 34936018
[TBL] [Abstract][Full Text] [Related]
5. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
7. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.
Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067
[TBL] [Abstract][Full Text] [Related]
8. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease.
Walker JP; Nosova E; Sigovan M; Rapp J; Grenon MS; Owens CD; Gasper WJ; Saloner DA
Ann Vasc Surg; 2015 Jan; 29(1):63-8. PubMed ID: 25269682
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
Ning P; Zucker EJ; Wong P; Vasanawala SS
Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
[TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients.
Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
Eur Radiol; 2018 Jan; 28(1):115-123. PubMed ID: 28677065
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MR lymphangiography: feasibility of using ferumoxytol in patients with chronic kidney disease.
Yekeler E; Krishnamurthy G; Smith CL; Escobar FA; Pinto E; Rapp JB; Otero HJ; White AM; Dori Y; Biko DM
Eur Radiol; 2022 Apr; 32(4):2564-2571. PubMed ID: 35001156
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
Adams LC; Jayapal P; Ramasamy SK; Morakote W; Yeom K; Baratto L; Daldrup-Link HE
AJR Am J Roentgenol; 2023 Apr; 220(4):590-603. PubMed ID: 36197052
[TBL] [Abstract][Full Text] [Related]
13. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.
Muehe AM; Feng D; von Eyben R; Luna-Fineman S; Link MP; Muthig T; Huddleston AE; Neuwelt EA; Daldrup-Link HE
Invest Radiol; 2016 Apr; 51(4):221-227. PubMed ID: 26656202
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular MRI with ferumoxytol.
Finn JP; Nguyen KL; Han F; Zhou Z; Salusky I; Ayad I; Hu P
Clin Radiol; 2016 Aug; 71(8):796-806. PubMed ID: 27221526
[TBL] [Abstract][Full Text] [Related]
15. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation.
Smits LP; Tiessens F; Zheng KH; Stroes ES; Nederveen AJ; Coolen BF
Atherosclerosis; 2017 Aug; 263():211-218. PubMed ID: 28662398
[TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.
Nguyen KL; Park EA; Yoshida T; Hu P; Finn JP
J Cardiovasc Magn Reson; 2017 Dec; 19(1):106. PubMed ID: 29284494
[TBL] [Abstract][Full Text] [Related]
18. Direct contrast-enhanced 3D MR venography evaluation of upper extremity deep venous system.
Tanju S; Sancak T; Düşünceli E; Yağmurlu B; Erden I; Sanlidilek U
Diagn Interv Radiol; 2006 Jun; 12(2):74-9. PubMed ID: 16752353
[TBL] [Abstract][Full Text] [Related]
19. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
[TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol MR Angiography versus Duplex US for Vascular Mapping before Arteriovenous Fistula Surgery for Hemodialysis.
Stoumpos S; Tan A; Hall Barrientos P; Stevenson K; Thomson PC; Kasthuri R; Radjenovic A; Kingsmore DB; Roditi G; Mark PB
Radiology; 2020 Oct; 297(1):214-222. PubMed ID: 32692301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
